J. Goldman & CO LP Biomarin Pharmaceutical Inc Transaction History

J. Goldman & CO LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $7.57 Million - $9.38 Million	-101,682 Reduced 76.23%	31,701 $2.61 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $10.8 Million - $12.7 Million	128,549 Added 2659.27%	133,383 $11.6 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $368,447 - $476,197	4,834 New	4,834 $466,000
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $434,256 - $526,999	-5,811 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $421,936 - $524,152	5,811 New	5,811 $510,000
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $156,892 - $286,038	-2,183 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $173,657 - $271,172	2,183 New	2,183 $269,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.